← ANALYST RATINGS · TIPRANKS
Kazia Therapeutics (KZIA): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $29.00, the highest $40.00, the lowest $18.00. The average is +300.0% from the last price of $7.25.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Sean Lee CFA★★★★★★★★★★#10658 · hits 30% · avg −1.5% | H.C. Wainwright | $18.00 | Buy | +148.3% | Reiterated | 01.10.26on TipRanks 10:20 | −1.5%next day −2.9% · 5 days −8.2% | ↗ |
| Kambiz Yazdi★★★★★★★★★★#1181 · hits 67% · avg +24.8% | BTIG | $40.00 | Buy | +451.7% | Reiterated | 22.09.26on TipRanks Sep 23 05:55 | +2.6%next day −11.4% · 5 days −9.5% | ↗ |
| John Newman★★★★★★★★★★#3035 · hits 44% · avg +4.1% | Canaccord Genuity | $29.00 | Buy | +300.0% | Reiterated | 01.09.26on TipRanks Aug 28 09:11 | −19.4%next day +1.7% · 5 days −9.5% | ↗ |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.00 | Sell | +65.5% | Downgrade | 04.08.26on TipRanks Aug 3 23:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.00 | Hold | +65.5% | Reiterated | 04.08.26on TipRanks Aug 3 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $12.00 | Hold | +65.5% | Upgrade | 04.08.26on TipRanks Aug 3 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $12.50 | Hold | +72.4% | Reiterated | 04.08.26on TipRanks Aug 3 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.50 | Hold | +72.4% | Reiterated | 04.08.26on TipRanks Aug 3 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $12.50 | Hold | +72.4% | Upgrade | 04.08.26on TipRanks Aug 3 23:05 | — | |
| Naz Rahman★★★★★★★★★★#12198 · hits 36% · avg −7.5% | Maxim Group | $30.00 | Buy | +313.8% | Reiterated | 15.07.26on TipRanks Jul 16 12:55 | −0.6%next day −1.8% · 5 days +9.6% | ↗ |
| Chad Messer★★★★★★★★★★#9258 · hits 37% · avg −0.2% | Lake Street | $32.00 | Buy | +341.4% | Initiated | 11.06.26on TipRanks 07:50 | +7.3%next day +13.3% · 5 days +9.0% | ↗ |
| Yale Jen★★★★★★★★★★#11895 · hits 27% · avg −9.0% | Laidlaw | $25.00 | Buy | +244.8% | Initiated | 15.04.26on TipRanks 05:25 | +4.9%next day +9.0% · 5 days +13.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Kazia Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $29.25 at a price of $9.60 (+204.8%); now: $29.00 at $7.25 (+300.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 4 | 7 | 8 | 8 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · Healthcare
About Kazia Therapeutics
- CEO: John Friend
- Employees: 6
- Three International Towers, Sydney, NSW, 2000, AU
- www.kaziatherapeutics.com
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Data from the stock’s TipRanks forecast page, read 142 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗